Citation Impact
Citing Papers
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Cancer statistics, 2023
2023 Standout
Catalytic Asymmetric Three‐Component Synthesis of Homoallylic Amines
2013 StandoutNobel
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
2010 Standout
NF-κB signaling in inflammation
2017 Standout
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
Natural products: An evolving role in future drug discovery
2011 Standout
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Vaccines Against Drug Abuse
2011
Virus-like particles in vaccine development
2010
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
2003
Structure of Dengue Virus
2002 Standout
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013 Standout
Soft-Tissue Sarcomas in Adults
2005 Standout
Immunology and immunotherapy of colorectal cancer
2003
Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma
2000
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens
2001
Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies
2013
The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy
2009
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
RNA‐Directed Packaging of Enzymes within Virus‐like Particles
2010
On the Dependency of Cellular Protein Levels on mRNA Abundance
2016 Standout
Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) Results of Protocol E1293
1996
Glycoproteomic Analysis of Prostate Cancer Tissues by SWATH Mass Spectrometry Discovers N-acylethanolamine Acid Amidase and Protein Tyrosine Kinase 7 as Signatures for Tumor Aggressiveness
2014
Mass spectrometric protein maps for biomarker discovery and clinical research
2013
Can NF-κB be a target for novel and efficient anti-cancer agents?
2006
Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis
2004 Standout
Analysis of anticancer drugs: A review
2011 Standout
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
Non-Hodgkin lymphoma
2012
Versatile Virus-Like Particle Carrier for Epitope Based Vaccines
2010
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
2004
Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice
2010
Computational design of ligand-binding proteins with high affinity and selectivity
2013 StandoutNatureNobel
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
2009
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
1999 Standout
Hyperprogressive disease: recognizing a novel pattern to improve patient management
2018
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
2002
A Double-Blind Placebo-Controlled Trial of Granulocyte Colony-Stimulating Factor in Elderly Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study (9031)
1998
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
2005 Standout
Regulatory T Cells and Human Disease
2020 StandoutNobel
Phenotypic characterization of human colorectal cancer stem cells
2007 Standout
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection
2004 StandoutNobel
Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma
2008
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors
2013 StandoutScienceNobel
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients
1996 StandoutNobel
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
2005 Standout
Immunologic and Clinical Responses to Rituximab in a Child With Opsoclonus-Myoclonus Syndrome
2004
Diverse Hepatitis C Virus Glycoproteins Mediate Viral Infection in a CD81-Dependent Manner
2004 StandoutNobel
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Immunodrugs: Therapeutic VLP-Based Vaccines for Chronic Diseases
2008
Perioperative Systemic Therapy for Resectable Non–Small Cell Lung Cancer
2022
Cancer treatment and survivorship statistics, 2016
2016 Standout
Applications of targeted proteomics in systems biology and translational medicine
2015
Quantitative measurements of N ‐linked glycoproteins in human plasma by SWATH ‐MS
2013
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Structural Investigations into the Stereochemistry and Activity of a Phenylalanine-2,3-aminomutase from Taxus chinensis
2014 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Growth of Pseudotypes of Vesicular Stomatitis Virus with N-Tropic Murine Leukemia Virus Coats in Cells Resistant to N-Tropic Viruses
1973 StandoutNobel
MSN Anti‐Cancer Nanomedicines: Chemotherapy Enhancement, Overcoming of Drug Resistance, and Metastasis Inhibition
2013
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
1997
Ribonucleic Acud Polymerase in Virions of Newcastle Disease Virus: Comparison with the Vesicular Stomatitis Virus Polymerase
1971 StandoutNobel
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
2011
Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
2003 StandoutNobel
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
2015 Standout
Design of a hyperstable 60-subunit protein icosahedron
2016 StandoutNatureNobel
Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studies
2015
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
2005 Standout
Alanine Scanning of the Hepatitis C Virus Core Protein Reveals Numerous Residues Essential for Production of Infectious Virus
2007 StandoutNobel
Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses
2006 StandoutNobel
Low-Dose Adenovirus Vaccine Encoding Chimeric Hepatitis B Virus Surface Antigen-Human Papillomavirus Type 16 E7 Proteins Induces Enhanced E7-Specific Antibody and Cytotoxic T-Cell Responses
2005 StandoutNobel
Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.
1992 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Chemical Glycoproteomics
2016 StandoutNobel
Cytokine-induced radiation protection and sensitization
1996
Works of Thomas Cerny being referenced
Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98
2010
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
2006
Rapid determination of gemcitabine in plasma and serum using reversed‐phase HPLC
2007
A Vaccine against Nicotine for Smoking Cessation: A Randomized Controlled Trial
2008
Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy
1999
Novel Prognostic Markers in the Serum of Patients With Castration-Resistant Prostate Cancer Derived From Quantitative Analysis of the Pten Conditional Knockout Mouse Proteome
2011
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors
2006
Mechanism of action of rituximab
2002
Docetaxel (TaxotereTM) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG)
1994
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignancies.
1994
Weekly x 4 Induction Therapy with the Anti-CD20 Antibody Rituximab: Effect on Circulating t(14;18)+ Follicular Lymphoma Cells
2001
Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3weeks in solid tumours: An ECSG/EORTC study
2005
Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine
2010
Effect of Single-Agent Rituximab Given at the Standard Schedule or As Prolonged Treatment in Patients With Mantle Cell Lymphoma: A Study of the Swiss Group for Clinical Cancer Research (SAKK)
2004
Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK)
2005